EVEREST MEDICINES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.65 HKD | +2.28% |
|
+14.39% | +17.94% |
| Apr. 25 | Everest Medicines' Loss Widens in 2023 | MT |
| Mar. 28 | Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
ETFs positioned on Everest Medicines Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.75% | 4 M€ | -27.92% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - |
Everest Medicines Ltd is a China-based company principally engaged in the licensing, clinical development and commercialization of therapies to address critical unmet medical needs. The Company is focusing on the research and development of innovative drug candidate. The Company built a portfolio of promising clinical-stage drug candidates across oncology, immunology, cardio-renal disease and infectious disease. The Company mainly provides its products and services in Greater China and other emerging Asia Pacific markets.
Sector
Pharmaceuticals
Calendar
2024-06-21
- CMBIS Healthcare Virtual Corporate Day
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
22.82
CNY
Average target price
25.92
CNY
Spread / Average Target
+13.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.94% | 1.01B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 1952 Stock
- Funds and ETFs Everest Medicines Limited
